Dean F Bajorin1, J Alfred Witjes1, Jürgen E Gschwend1, Michael Schenker1, Begoña P Valderrama1, Yoshihiko Tomita1, Aristotelis Bamias1, Thierry Lebret1, Shahrokh F Shariat1, Se Hoon Park1, Dingwei Ye1, Mads Agerbaek1, Deborah Enting1, Ray McDermott1, Pablo Gajate1, Avivit Peer1, Matthew I Milowsky1, Alexander Nosov1, João Neif Antonio1, Krzysztof Tupikowski1, Laurence Toms1, Bruce S Fischer1, Anila Qureshi1, Sandra Collette1, Keziban Unsal-Kacmaz1, Edward Broughton1, Dimitrios Zardavas1, Henry B Koon1, Matthew D Galsky1. 1. From the Memorial Sloan Kettering Cancer Center (D.F.B), Weill Cornell Medical College (S.F.S.), and Icahn School of Medicine at Mount Sinai (M.D.G.) - all in New York; Radboud University, Nijmegen, the Netherlands (J.A.W.); the Department of Urology, Technical University Munich, Munich, Germany (J.E.G.); Nectarie Oncology Center, Craiova, Romania (M.S.); Hospital Universitario Virgen del Rocío, Seville (B.P.V.), and Ramon y Cajal University Hospital, Madrid (P.G.) - both in Spain; Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan (Y.T.); National and Kapodistrian University of Athens, Athens (A.B.); the Urology Department, Hôpital Foch, Université Paris-Saclay, Université Versailles Saint-Quentin-en-Yvelines, Versailles, France (T.L.); Medical University of Vienna, Vienna General Hospital, Vienna (S.F.S.); University of Texas Southwestern Medical Center, Dallas (S.F.S.); Charles University, Prague, Czech Republic (S.F.S.); the Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow (S.F.S.), and Federal State Budget Institution N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health Care of the Russian Federation, St. Petersburg (A.N.) - both in Russia; Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Fudan University Shanghai Cancer Center, Shanghai, China (D.Y.); Aarhus University Hospital, Aarhus, Denmark (M.A.); Guy's and St. Thomas' NHS Foundation Trust, London (D.E.); St. Vincent's University Hospital and Cancer Trials Ireland, Dublin (R.M.); Rambam Health Care Campus, Haifa, Israel (A.P.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (M.I.M.); Hospital de Amor de Barretos-Pio XII Foundation, Barretos, Brazil (J.N.A.); the Subdivision of Urology, Wroclaw Comprehensive Cancer Center, Wroclaw, Poland (K.T.); and Bristol Myers Squibb, Princeton, NJ (L.T., B.S.F., A.Q., S.C., K.U.-K., E.B., D.Z., H.B.K.).
Abstract
BACKGROUND: The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. METHODS: In a phase 3, multicenter, double-blind, randomized, controlled trial, we assigned patients with muscle-invasive urothelial carcinoma who had undergone radical surgery to receive, in a 1:1 ratio, either nivolumab (240 mg intravenously) or placebo every 2 weeks for up to 1 year. Neoadjuvant cisplatin-based chemotherapy before trial entry was allowed. The primary end points were disease-free survival among all the patients (intention-to-treat population) and among patients with a tumor programmed death ligand 1 (PD-L1) expression level of 1% or more. Survival free from recurrence outside the urothelial tract was a secondary end point. RESULTS: A total of 353 patients were assigned to receive nivolumab and 356 to receive placebo. The median disease-free survival in the intention-to-treat population was 20.8 months (95% confidence interval [CI], 16.5 to 27.6) with nivolumab and 10.8 months (95% CI, 8.3 to 13.9) with placebo. The percentage of patients who were alive and disease-free at 6 months was 74.9% with nivolumab and 60.3% with placebo (hazard ratio for disease recurrence or death, 0.70; 98.22% CI, 0.55 to 0.90; P<0.001). Among patients with a PD-L1 expression level of 1% or more, the percentage of patients was 74.5% and 55.7%, respectively (hazard ratio, 0.55; 98.72% CI, 0.35 to 0.85; P<0.001). The median survival free from recurrence outside the urothelial tract in the intention-to-treat population was 22.9 months (95% CI, 19.2 to 33.4) with nivolumab and 13.7 months (95% CI, 8.4 to 20.3) with placebo. The percentage of patients who were alive and free from recurrence outside the urothelial tract at 6 months was 77.0% with nivolumab and 62.7% with placebo (hazard ratio for recurrence outside the urothelial tract or death, 0.72; 95% CI, 0.59 to 0.89). Among patients with a PD-L1 expression level of 1% or more, the percentage of patients was 75.3% and 56.7%, respectively (hazard ratio, 0.55; 95% CI, 0.39 to 0.79). Treatment-related adverse events of grade 3 or higher occurred in 17.9% of the nivolumab group and 7.2% of the placebo group. Two treatment-related deaths due to pneumonitis were noted in the nivolumab group. CONCLUSIONS: In this trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, disease-free survival was longer with adjuvant nivolumab than with placebo in the intention-to-treat population and among patients with a PD-L1 expression level of 1% or more. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 274 ClinicalTrials.gov number, NCT02632409.).
BACKGROUND: The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. METHODS: In a phase 3, multicenter, double-blind, randomized, controlled trial, we assigned patients with muscle-invasive urothelial carcinoma who had undergone radical surgery to receive, in a 1:1 ratio, either nivolumab (240 mg intravenously) or placebo every 2 weeks for up to 1 year. Neoadjuvant cisplatin-based chemotherapy before trial entry was allowed. The primary end points were disease-free survival among all the patients (intention-to-treat population) and among patients with a tumor programmed death ligand 1 (PD-L1) expression level of 1% or more. Survival free from recurrence outside the urothelial tract was a secondary end point. RESULTS: A total of 353 patients were assigned to receive nivolumab and 356 to receive placebo. The median disease-free survival in the intention-to-treat population was 20.8 months (95% confidence interval [CI], 16.5 to 27.6) with nivolumab and 10.8 months (95% CI, 8.3 to 13.9) with placebo. The percentage of patients who were alive and disease-free at 6 months was 74.9% with nivolumab and 60.3% with placebo (hazard ratio for disease recurrence or death, 0.70; 98.22% CI, 0.55 to 0.90; P<0.001). Among patients with a PD-L1 expression level of 1% or more, the percentage of patients was 74.5% and 55.7%, respectively (hazard ratio, 0.55; 98.72% CI, 0.35 to 0.85; P<0.001). The median survival free from recurrence outside the urothelial tract in the intention-to-treat population was 22.9 months (95% CI, 19.2 to 33.4) with nivolumab and 13.7 months (95% CI, 8.4 to 20.3) with placebo. The percentage of patients who were alive and free from recurrence outside the urothelial tract at 6 months was 77.0% with nivolumab and 62.7% with placebo (hazard ratio for recurrence outside the urothelial tract or death, 0.72; 95% CI, 0.59 to 0.89). Among patients with a PD-L1 expression level of 1% or more, the percentage of patients was 75.3% and 56.7%, respectively (hazard ratio, 0.55; 95% CI, 0.39 to 0.79). Treatment-related adverse events of grade 3 or higher occurred in 17.9% of the nivolumab group and 7.2% of the placebo group. Two treatment-related deaths due to pneumonitis were noted in the nivolumab group. CONCLUSIONS: In this trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, disease-free survival was longer with adjuvant nivolumab than with placebo in the intention-to-treat population and among patients with a PD-L1 expression level of 1% or more. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 274 ClinicalTrials.gov number, NCT02632409.).
Authors: Joaquim Bellmunt; Maha Hussain; Jürgen E Gschwend; Peter Albers; Stephane Oudard; Daniel Castellano; Siamak Daneshmand; Hiroyuki Nishiyama; Martin Majchrowicz; Viraj Degaonkar; Yi Shi; Sanjeev Mariathasan; Petros Grivas; Alexandra Drakaki; Peter H O'Donnell; Jonathan E Rosenberg; Daniel M Geynisman; Daniel P Petrylak; Jean Hoffman-Censits; Jens Bedke; Arash Rezazadeh Kalebasty; Yousef Zakharia; Michiel S van der Heijden; Cora N Sternberg; Nicole N Davarpanah; Thomas Powles Journal: Lancet Oncol Date: 2021-03-12 Impact factor: 41.316
Authors: Atreya Dash; Matthew D Galsky; Andrew J Vickers; Angel M Serio; Theresa M Koppie; Guido Dalbagni; Bernard H Bochner Journal: Cancer Date: 2006-08-01 Impact factor: 6.860
Authors: Harun Fajkovic; Eugene K Cha; Evanguelos Xylinas; Michael Rink; Armin Pycha; Christian Seitz; Christian Bolenz; Allison Dunning; Giacomo Novara; Quoc-Dien Trinh; Pierre I Karakiewicz; Vitaly Margulis; Jay D Raman; Thomas J Walton; Shiro Baba; Joaquin Carballido; Wolfgang Otto; Francesco Montorsi; Yair Lotan; Wassim Kassouf; Hans-Martin Fritsche; Karim Bensalah; Richard Zigeuner; Douglas S Scherr; Guru Sonpavde; Morgan Roupret; Shahrokh F Shariat Journal: World J Urol Date: 2012-09-26 Impact factor: 4.226
Authors: Shahrokh F Shariat; Pierre I Karakiewicz; Ganesh S Palapattu; Yair Lotan; Craig G Rogers; Gilad E Amiel; Amnon Vazina; Amit Gupta; Patrick J Bastian; Arthur I Sagalowsky; Mark P Schoenberg; Seth P Lerner Journal: J Urol Date: 2006-12 Impact factor: 7.450
Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Evanguelos Xylinas; Michael Rink; Vitaly Margulis; Thomas Clozel; Richard K Lee; Evi Comploj; Giacomo Novara; Jay D Raman; Yair Lotan; Alon Weizer; Morgan Roupret; Armin Pycha; Douglas S Scherr; Christian Seitz; Vincenzo Ficarra; Quoc-Dien Trinh; Pierre I Karakiewicz; Francesco Montorsi; Marc Zerbib; Shahrokh F Shariat Journal: BJU Int Date: 2013-03-06 Impact factor: 5.588
Authors: J Alfred Witjes; Thierry Lebret; Eva M Compérat; Nigel C Cowan; Maria De Santis; Harman Maxim Bruins; Virginia Hernández; Estefania Linares Espinós; James Dunn; Mathieu Rouanne; Yann Neuzillet; Erik Veskimäe; Antoine G van der Heijden; Georgios Gakis; Maria J Ribal Journal: Eur Urol Date: 2016-06-30 Impact factor: 20.096
Authors: Padmanee Sharma; Margaret K Callahan; Petri Bono; Joseph Kim; Pavlina Spiliopoulou; Emiliano Calvo; Rathi N Pillai; Patrick A Ott; Filippo de Braud; Michael Morse; Dung T Le; Dirk Jaeger; Emily Chan; Chris Harbison; Chen-Sheng Lin; Marina Tschaika; Alex Azrilevich; Jonathan E Rosenberg Journal: Lancet Oncol Date: 2016-10-09 Impact factor: 41.316
Authors: Francesco Chierigo; Marco Borghesi; Christoph Würnschimmel; Rocco Simone Flammia; Benedikt Horlemann; Gabriele Sorce; Benedikt Hoeh; Zhe Tian; Fred Saad; Markus Graefen; Michele Gallucci; Alberto Briganti; Francesco Montorsi; Felix K H Chun; Shahrokh F Shariat; Guglielmo Mantica; Nazareno Suardi; Carlo Terrone; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2022-05-04 Impact factor: 2.370
Authors: Shabaz Sultan; Mark A J Gorris; I Jolanda M de Vries; Niven Mehra; Sandra van Wilpe; Diederik M Somford; Heidi V N Kusters-Vandevelde; Rutger H T Koornstra; Winald R Gerritsen; Michiel Simons; Antoine G van der Heijden Journal: Cancer Immunol Immunother Date: 2022-06-30 Impact factor: 6.968
Authors: Guru P Sonpavde; Benjamin Louis Maughan; Bradley Alexander McGregor; Xiao X Wei; Kerry L Kilbridge; Richard J Lee; Evan Y Yu; Michael Thomas Schweizer; Robert B Montgomery; Heather H Cheng; Andrew Caleb Hsieh; Rohit Jain; Jaspreet S Grewal; Cesar Pico-Navarro; Zarina Gafoor; Teresa Perschy; Petros Grivas Journal: Cancer Immunol Immunother Date: 2022-08-23 Impact factor: 6.630
Authors: Giorgio Ivan Russo; Nicolò Musso; Arturo Lo Giudice; Maria Giovanna Asmundo; Marina Di Mauro; Paolo G Bonacci; Mariacristina Massimino; Dalida Bivona; Stefania Stefani; Elisabetta Pricoco; Matteo Ferro; Massimo Camarda; Sebastiano Cimino; Giuseppe Morgia; Rosario Caltabiano; Giuseppe Broggi Journal: J Cancer Res Clin Oncol Date: 2022-08-16 Impact factor: 4.322
Authors: Yu Fujiwara; Nobuyuki Horita; Matthew Harrington; Ho Namkoong; Hirotaka Miyashita; Matthew D Galsky Journal: Cancer Immunol Immunother Date: 2022-04-26 Impact factor: 6.630
Authors: Chana Weinstock; Matthew D Galsky; Elaine Chang; Andrea B Apolo; Rick Bangs; Stephanie Chisolm; Vinay Duddalwar; Jason A Efstathiou; Kirsten B Goldberg; Donna E Hansel; Ashish M Kamat; Paul G Kluetz; Seth P Lerner; Elizabeth Plimack; Tatiana Prowell; Harpreet Singh; Daniel Suzman; Evan Y Yu; Hui Zhang; Julia A Beaver; Richard Pazdur Journal: Nat Rev Urol Date: 2021-09-10 Impact factor: 14.432
Authors: Tracy L Rose; Michael R Harrison; Allison M Deal; Sundhar Ramalingam; Young E Whang; Blaine Brower; Mary Dunn; Chelsea K Osterman; Hillary M Heiling; Marc A Bjurlin; Angela B Smith; Matthew E Nielsen; Hung-Jui Tan; Eric Wallen; Michael E Woods; Daniel George; Tian Zhang; Anthony Drier; William Y Kim; Matthew I Milowsky Journal: J Clin Oncol Date: 2021-08-24 Impact factor: 50.717